Form4insider filings, from the source

SEC Form 3 · accession 0001209191-15-032493

Aegerion Pharmaceuticals, Inc. · AEGR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mary Weger
Officer — Chief Performance Officer
Period of report
Mar 29, 2015
Accepted (ET)
Apr 3, 2015 · 7:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———3,038D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)$15.95holding———Dec 31, 2014Jan 23, 2022Common Stock45,000—D
Stock Option (right to buy)F1$16.28holding————Jan 3, 2022Common Stock75,000—D
Stock Option (right to buy)F2$22.35holding————Nov 1, 2022Common Stock40,000—D
Stock Option (right to buy)F3$39.02holding————Apr 1, 2023Common Stock20,000—D
Stock Option (right to buy)F4$47.11holding————Apr 1, 2024Common Stock13,000—D
Stock Option (right to buy)F5$20.93holding————Nov 3, 2024Common Stock40,000—D

Explanation of responses